Preferred Provider Status for Atlantic Research Group
February 1, 2018Challenge: A specialty biopharmaceutical company targeting the therapeutic power of plasma for the treatment of chronic, life-altering diseases like hemophilia and immune deficiencies, contracted with ARG to perform CRO services for two different Phase III studies. Regulatory requirements included an audit mid-way through the process.
Results: ARG won preferred provider status after successfully completing an audit of protocol design, conduct, monitoring, data management, and quality assurance processes.
Lessons Learned: Equal expertise is multiple functional areas clearly demonstrates ARG team experience, commitment, and execution.
